Vaccine technologies company TapImmune has reported that positive interim safety analysis was achieved in breast cancer patients treated with HER2/neu antigens.
The analysis conducted on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, did not establish any serious adverse events.
TapImmune CEO Glynn Wilson said obtaining positive interim data is an important milestone for the programme.
"As we move through clinical development it is essential that we clear these early safety hurdles and move towards development of our complete HER2/neu vaccine," Wilson said.
The company will now progress the treatment of the remaining 17 patients in the Phase I study.
HER2/neu Class II antigens show high affinity binding to human major histocompatibility complex (MHC) proteins for around 84% of the population, making it potentially applicable to a wide range of HER2/neu patients compared to other approaches.
Breast cancer patients who finished standard Herceptin-based therapy and are at risk of disease recurrence are participating in the trial.
Safety and immunogenicity are the primary endpoints of the study
TapImmune has an exclusive option to license the antigen technology at the end of Phase I.